SSA
EFTR

Schonfeld Strategic Advisors’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,131
Closed -$1.24M – 2406
2021
Q1 		$1.24M Buy
+5,131
New +$1.26M 0.02% 813

Other funds holding EFTR

ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Schonfeld Strategic Advisors's EFTR Position: Q2 2021 in Review

Schonfeld Strategic Advisors sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2021, closing a stake of 5,131 shares — an estimated $1.24M sold.

Schonfeld Strategic Advisors first reported a position in EFTR in Q1 2021 and held it in 1 quarter. The position peaked at $1.24M in Q1 2021. 58 funds tracked by Wall St. Rank hold EFTR as of Q2 2021.

  • Schonfeld Strategic Advisors reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 5,131 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1.24M.
  • Schonfeld Strategic Advisors first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $1.24M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.